News Center
With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.
13
2024
-
08
Tide Sip Focus Market | Keyuan Pharmaceutical & lino Pharmaceutical Exchange and Cooperation with Partners at 2024 Sip Conference!
Classification：
News
行业新闻
Corporate News
Recently, the high-profile2024 SipuIn Boao, Hainan, Keyuan Pharmaceutical (stock code: 301281.SZ)-lino pharmaceutical as a pioneer in the innovation and development of digital medicine, and from the health industry.Many elites, leading enterprises, partnersExchange and discussion, and work together to promote the in-depth cooperation and transformation and upgrading of the health industry.
in great healthDeep industrial changeIn the context of the environment, Keyuan Pharmaceuticals and lino Pharmaceuticals are in.Digital and intelligent transformationRemarkable results have been achieved.
Companies actively explore digital, intelligent technology inInnovative R & D, production, sales and medical servicesand other aspects of the application, a large number of the introduction of the world's leadingAutomatic production equipment and production management system, to realize the digital management of the whole business process,Improve the company's production efficiency, product quality and management efficiency,Lay a solid foundation for it to open up a new situation and achieve new breakthroughs in the fierce market competition.
At this Sipu meeting, Keyuan Pharmaceuticals & Lino Pharmaceuticals shared itsMarket strategy and product layoutaspects of new ideas. Chairman and President of Keyuan Pharmaceuticals, Chairman of Liino PharmaceuticalsJiang Hongsheng leads the marketing teamActive and many.Industry leaders, business executivesIn-depth exchanges were conducted to discuss the future development direction and incremental market of the health industry.Expand your business and deepen your relationships.
A number of partners have highly recognized the development achievements of Keyuan Pharmaceuticals & lino Pharmaceuticals, and haveexpressed the willingness to cooperate in depth. They believe that Keyuan Pharmaceuticals and lino Pharmaceuticals are in.Successful Practice of Digital Intelligence TransformationIt has set a benchmark for the whole health industry and provided the future development of the industry.useful reference and enlightenment.
With the continuous development of the global health industry, Keyuan Pharmaceuticals & lino Pharmaceuticals will continue to upholdInnovation, openness and cooperationThe concept of continuing to focus on segments of the health industry,Dig deeper into market demandStrengthening collaboration with partners,Driving innovation and upgrading of products and servicesTo jointly create a new ecology and a new future for the health industry.
Last article
Related news
2026-05-18
On May 16–17, Wu Xiaobo, known as “China’s foremost financial writer” and a renowned entrepreneur, led a delegation to visit and inspect Keyuan Pharmaceutical (stock code: 301281.SZ). The group focused on the company’s achievements in integrating smart manufacturing with digital AI technologies in the pharmaceutical sector, engaged in in-depth discussions with its core management team, and expressed high praise for the company’s practical approach to driving industrial upgrading through digital and intelligent transformation. Gao Yuankun, Chairman and President of Linuo Group, along with Li Hongfu, Chairman of Keyuan Pharmaceutical, and Wei Zhiguo, President of the company, accompanied the delegation during the visit.
ADD：#30766 Jingshidong Road, Linuo High-tech Park, Jinan, Shandong Province, P. R. China